Want to see HK:2496 full AI Analyst Report?
2496 Stock Chart & Stats
HK$3.30
-HK$0.11(-2.89%)
At close: 4:00 PM EDT
HK$3.30
-HK$0.11(-2.89%)
Day’s Range― - ―
52-Week RangeHK$0.96 - HK$8.50
Previous CloseN/A
Volume200.00
Average Volume (3M)220.00
Market Cap
HK$864.14M
Enterprise ValueHK$809.03
Total Cash (Recent Filing)HK$75.98M
Total Debt (Recent Filing)HK$138.62M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding179,479,110
10 Day Avg. Volume0
30 Day Avg. Volume220
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)-26.32
Price to Sales (P/S)21.44
P/FCF Ratio-62.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnThe sharp reduction in operating and free cash burn indicates improved cost control or working-capital performance. Although cash generation remains negative, a lower funding requirement could extend liquidity and provide more time for the business to restore operations.
Losses Improved Versus Prior YearsImprovement from the most severe prior-year losses suggests some progress in reducing the intensity of earnings deterioration. This does not establish profitability, but continued improvement could support eventual stabilization if revenue and margins recover.
Positive EPS Growth MetricThe reported positive EPS growth metric provides evidence of year-over-year improvement in per-share earnings performance, even though the company remains loss-making. If sustained, this trend could help narrow losses and strengthen future earnings quality.
Bears Say
Sharp Revenue ContractionA revenue decline of this magnitude signals substantial weakening in commercial performance and reduces the scale available to support research, operations, and fixed costs. Persistent top-line contraction would make a durable return to profitability materially harder.
Severe Margin DeteriorationThe collapse in gross margin shows that the remaining revenue is generating far less economic value than before, while the deeply negative net margin confirms losses remain severe. Without structural margin recovery, growth would not readily translate into self-funded earnings.
Negative Equity And Higher DebtNegative equity combined with materially higher debt weakens solvency and restricts financial flexibility. The company has less balance-sheet capacity to absorb continued losses, and its ability to fund operations or growth without additional external capital is more constrained.
Wuhan YZY Biopharma Co., Ltd. Class H News
2496 FAQ
What was Wuhan YZY Biopharma Co., Ltd. Class H’s price range in the past 12 months?
Wuhan YZY Biopharma Co., Ltd. Class H lowest stock price was HK$0.96 and its highest was HK$8.50 in the past 12 months.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s market cap?
Wuhan YZY Biopharma Co., Ltd. Class H’s market cap is HK$864.14M.
When is Wuhan YZY Biopharma Co., Ltd. Class H’s upcoming earnings report date?
Wuhan YZY Biopharma Co., Ltd. Class H’s upcoming earnings report date is Mar 26, 2027 which is in 183 days.
How were Wuhan YZY Biopharma Co., Ltd. Class H’s earnings last quarter?
Wuhan YZY Biopharma Co., Ltd. Class H released its earnings results on Aug 28, 2026. The company reported -HK$0.037 earnings per share for the quarter.
Is Wuhan YZY Biopharma Co., Ltd. Class H overvalued?
According to Wall Street analysts Wuhan YZY Biopharma Co., Ltd. Class H’s price is currently Overvalued.
Does Wuhan YZY Biopharma Co., Ltd. Class H pay dividends?
Wuhan YZY Biopharma Co., Ltd. Class H does not currently pay dividends.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate?
Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wuhan YZY Biopharma Co., Ltd. Class H have?
Wuhan YZY Biopharma Co., Ltd. Class H has 179,479,110 shares outstanding.
What happened to Wuhan YZY Biopharma Co., Ltd. Class H’s price movement after its last earnings report?
Wuhan YZY Biopharma Co., Ltd. Class H reported an EPS of -HK$0.037 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wuhan YZY Biopharma Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2496
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wuhan YZY Biopharma Co., Ltd. Class H
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Technical Analysis
Brii Biosciences Limited
―
3D Medicines, Inc.
―
Mabpharm Limited
―
Transcenta Holding Limited
―
Sunho Biologics,Inc.
―